Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection

Hepatology

Volumn 54, Issue 4, 2011, Pages 1127-1134

  Marabita, Francesco ^a   Aghemo, Alessio ^b   de Nicola, Stella ^b   Rumi, Maria G ^b   Cheroni, Cristina ^a   Scavelli, Rossana ^a   Crimi, Marco ^a   Soffredini, Roberta ^b   Abrignani, Sergio ^a   de Francesco, Raffaele ^a   Colombo, Massimo ^b  

^a Istituto Nazionale di Genetica Molecolare   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CHILD; DISEASE COURSE; ENVIRONMENTAL FACTOR; FATTY LIVER; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HOST; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS TRANSMISSION;

ADULT; AGE DISTRIBUTION; AGE OF ONSET; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; LINEAR MODELS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; YOUNG ADULT;

EID: 80053308776     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24503     Document Type: Article

References (32)

1. Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36: S35-S46.
2. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008; 134: 1699-714.
3. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-666.
4. De Nicola S, Aghemo A, Rumi MG, Colombo M. HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 964-966.
5. Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. HEPATOLOGY 2009; 50: 1038-1044.
6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
7. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
8. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
9. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345, 1345e1-e7.
10. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461: 798-801.
11. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB. Hepatitis C pharmacogenetics: State of the art in 2010. HEPATOLOGY 2011; 53: 336-345.
12. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2009. Available at:.
13. Terry Therneau and original R port by Thomas Lumley. Survival: survival analysis, including penalised likelihood. R package version 2.35-7. 2009. Available at: Accessed on February 18, 2011.
14. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.
15. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-739.
16. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, et al., HENCORE collaboration. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003; 52: 574-579.
17. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. HEPATOLOGY 2010; 51: 1904-1911.
18. IL28B genetic polymorphism has genome wide significant associations with serum low density lipoprotein levels and hepatic steatosis in patients with genotype 1 chronic hepatitis C. HEPATOLOGY 2010; 52(Suppl 1): 439A.
19. Stättermayer A, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Hofer H, et al. Influence of IL28B-genotype on insulin resistance in treatment-naïve patients with chronic hepatitis C [Abstract]. HEPATOLOGY 2010; 52(Suppl 1): 1224A.
20. Bitetto D, Fabris C, Fornasiere E, Fumolo E, Cussigh A, Bignulin S, et al. IL28B rs12979860 C>T polymorphism affects the evolution of chronic hepatitis C [Abstract]. HEPATOLOGY 2010; 52(Suppl 1): 438A.
21. Del Campo JA, Maraver Zamora M, Ramírez-Lorca R, Pardo-Yules B, Sáez ME, Real LM. IL28B polymorphism predicts sustained virological response in hepatitis C but is not associated with fibrosis or viral load [Abstract]. HEPATOLOGY 2010; 52(Suppl 1): 748A.
22. Thompson AJ, Clark PJ, Fellay J, Muir AJ, Tillmann HL, Patel K, et al. IL28B genotype is not associated with advanced hepatic fibrosis in chronic hepatitis C patients enrolled in the ideal study [Abstract]. HEPATOLOGY 2010; 52(Suppl 1): 437A.
23. Thompson AJ, Clark PJ, Zhu M, Zhu Q, Ge D, Sulkowski MS, et al. Genome-wide association study identifies IL28B polymorphism to be associated with baseline alt and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study [Abstract]. HEPATOLOGY 2010; 52(Suppl 1): 1220A.
24. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
25. Casiraghi MA, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, Zanetti AR. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. HEPATOLOGY 2004; 39: 90-96.
26. Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection. J Infect Dis 2000; 181: 419-424.
27. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male P-J, Giostra E, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 406-412.
28. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
29. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. HEPATOLOGY 2005; 41: 82-87.
30. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterology 2002; 97: 2614-2618.
31. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134: 1670-1681.
32. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3.